BioAmber Announces Trading on Toronto Stock Exchange Market Commencing on May 3, 2017 - Special Warrant Automatically Exercised
May 2, 2017
MONTREAL, May 2, 2017 /CNW Telbec/ - BioAmber Inc. ("BioAmber" or the "Company") (NYSE: BIOA & TSX: BIOA) is pleased to announce that its common stock ("Common Shares") will begin trading on the TSX under the symbol "BIOA" beginning May 3, 2017. . The CUSIP number will be 09072Q106, the same CUSIP as the Common Shares currently traded on the New York Stock Exchange ("NYSE").
BioAmber's previously issued special warrant (the "Special Warrant") was automatically exercised, on April 28, 2017, for 2,224,199 Common Shares (the "Underlying Shares") following the issuance of a receipt for its final prospectus qualifying the Underlying Shares by the British Columbia Securities Commission.
The Special Warrant was issued in a private placement on December 30, 2016, at a price of US$4.00 per Underlying Share issuable upon the exercise of the Special Warrant, resulting in gross proceeds to the Company of US$8,896,796. The proceeds were placed in escrow and were released to the Company concurrently with the automatic exercise of the Special Warrant.
BioAmber (NYSE: BIOA & TSX: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products. For more information visit www.bio-amber.com.
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond BioAmber's control. BioAmber's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors.
Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For additional disclosure regarding these and other risks faced by BioAmber, see disclosures contained in BioAmber's public filings (i) with the SEC, including the "Risk Factors" section of BioAmber's most recent Annual Report on Form 10-K, and (ii) with the British Columbia Securities Commission, including the "Risk Factors" section of BioAmber's prospectus dated April 27, 2017.
SOURCE BioAmber Inc.
For further information: BioAmber Investor Contact: Roy McDowall, Sr. VP Business Development, Tel (514) 844 8000 ext 260, firstname.lastname@example.org